A highly sensitive bone marrow test could double survival rates for some groups of younger adults with acute myeloid leukemia (AML) by helping doctors identify if they might relapse up to three months ...

Long-term survivors demonstrated clinically meaningful decrements in SF-36 physical functioning and role-physical scores versus general population norms, indicating persistent limitations in daily ...

Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2 nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L ...

Qlucore, listed on Nasdaq First North, announces the launch of a new Qlucore Insights test (Research Use Only) specifically developed for Acute Myeloid Leukemia (AML). The software-based test delivers ...

Targeted maintenance therapy with gilteritinib (Xospata; Astellas) following allogeneic hematopoietic stem cell ...

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma To our knowledge, this is the ...

Anthracycline and cytarabine chemotherapy has been the backbone of induction chemotherapy for AML for more than 50 years. Advances in our understanding of leukemia biology and the development of ...

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an early-phase ...

Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than those ...